BPR1M97 is a dual-acting mu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with K i values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects
In Vivo
BPR1M97 (1.8 mg/kg; s.c.; once) demonstrates antinociception in a murine model of cancer pain . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male wild-type C57BL/6 mice (25-30 g) Dosage: 1.8 mg/kg Administration: Subcutaneous injection (s.c.); once Result: Demonstrated antinociception in a murine model of cancer pain.
Form:Solid
IC50& Target:Ki: 1.8 nM (MOP), 4.2 nM (NOP)
规格
规格或纯度
≥98%
英文名称
BPR1M97
生化机理
BPR1M97 是一种双效μ阿片受体(MOP)和神经肽-orphanin FQ 肽(NOP)受体激动剂,其 K i 值分别为 1.8 和 4.2 nM。BPR1M97 具有很高的药效和血脑屏障穿透性,可产生强效的抗镇痛作用。